Front Pharmacol 2022;13:992713 doi: 10.3389/fphar.2022.992713
This is the largest meta-analysis to date, assessing the risk of OIs (Opportunistic infection) in patients with PsA. In coming to this conclusion, a systematic review and meta-analysis was undertaken to estimate the incidence of OIs following treatment with b- and tsDMARDs.
In addition, their results highlighted that bDMARDs and tsDMARDS had a low cumulative incidence of OIs in this patient group (<3% across all MOAs examined). The most common OI differed based on drug MOA. Continued evaluation of OIs is needed in post-marketing and longer-term trials to assess risk of uncommon OIs, or those with prolonged latent periods